Ask AI
ProCE Banner Activity

Do It Better: Managing Cardio–Renal–Metabolic Disease Early Improves Patient Outcomes

Clinical Thought

Learn why early identification of cardio–renal–metabolic disease is critical and how adding an SGLT2 inhibitor to patients’ regimens can help them beyond simply lowering their A1C for type 2 diabetes, including providing renal protection and inducing weight loss for those with comorbid chronic kidney disease or obesity, respectively.

Released: August 14, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Jay H. Shubrook, DO, FACOFP, FAAFP: consultant/advisor/speaker: Abbott, Bayer, Corcept, Insulet, Lilly, Madrigal, Novo Nordisk, Sanofi.